Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: CLL cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. EXPERIMENTAL DESIGN: Patients were eligible for this phase 2 trial if they had documented CLL/SLL and had failed a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Amrein, Philip C., Attar, Eyal C., Takvorian, Tak, Hochberg, Ephraim P., Ballen, Karen K., Leahy, Kathleen M., Fisher, David C., LaCasce, Ann S., Jacobsen, Eric D., Armand, Philippe, Hasserjian, Robert P., Werner, Lillian, Neuberg, Donna, Brown, Jennifer R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108904/
https://ncbi.nlm.nih.gov/pubmed/21402714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2879
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados